Compare Campbell Soup Co. (CPB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Viatris Inc — how do they compare? Campbell Soup Co. trades at $22.56 (market cap $6.78B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.8× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| CPB | VTRS | |
|---|---|---|
Market Cap | $6.78B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $17.86 |
52-Week Low | $20.00 | $9.49 |
Enterprise Value | $13.38B | $30.80B |
Dividend Yield | 6.87% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.42, down 2.73% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $0.50, beating expectations of $0.4789, while Q4 2025 missed estimates. Revenue reached $10.25B in 2025 with a net income margin of 6.12%, though profitability metrics like ROE (3.09%) remain modest. Recent news highlights product innovation with new protein soups and leadership transitions aimed at business transformation.
The outlook for CPB is cautious with a consensus price target of $20.20 below the current price, reflecting analyst skepticism (58.62% Hold, 37.93% Sell). Opportunities include cost-saving initiatives and a sustainable ~7% dividend yield, but risks involve margin pressures, high debt levels, and competitive challenges in the packaged foods sector. Investors should weigh the dividend appeal against structural profitability concerns.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
